Low-dose post-transplant cyclophosphamide and anti-thymocyte globulin as an effective strategy for GVHD prevention in haploidentical patients.
Yu WangDe-Pei WuQi-Fa LiuLan-Ping XuKai-Yan LiuXiao-Hui ZhangWen-Jing YuYang XuFen HuangXiao-Jun HuangPublished in: Journal of hematology & oncology (2019)
These results suggested that ATG/PTCy (low-dose) can reduce both acute and chronic GVHD as compared with standard ATG-based prophylaxis using maternal donor or collateral relatives at particular high GVHD risk.
Keyphrases
- low dose
- high dose
- end stage renal disease
- allogeneic hematopoietic stem cell transplantation
- newly diagnosed
- ejection fraction
- stem cell transplantation
- chronic kidney disease
- liver failure
- prognostic factors
- drug induced
- acute myeloid leukemia
- bone marrow
- respiratory failure
- acute lymphoblastic leukemia
- intensive care unit
- pregnant women
- birth weight
- patient reported outcomes
- hepatitis b virus
- mechanical ventilation
- patient reported
- preterm birth